Patients must have been previously evaluated with integrated molecular pathology.
Patients could not have been treated for pancreatic cancer prior to integrated molecular pathology.
Benign outcomes were defined as no evidence of malignancy after two or more years of clinical follow-up.
Malignant outcomes were determined by positive cytology, evidence of cancer from surgical pathology, or clinical cancer treatment.
|Length of follow up||Source of outcome|
|Surgical pathology||Positive cytology||Clinical cancer management||EUS/imaging surveillance|
Marc F. Catalano, M.D.
Mohammad A. Al-Haddad, M.D.
Sandeep K. Patel DO, Emuejevoke Okoh, M.D., C. Laura Rosenkranz, M.D.
Michael Karasik, M.D., Michael Golioto, M.D.
Thomas Kowalski, M.D., Ali Siddiqui, M.D., David Loren, M.D.
Jeffrey Linder, M.D.
Howard Mertz, M.D.
Mark J. Lybik, M.D.
Damien Mallat, M.D.
Nadim Haddad, M.D., Nidhi Malhotra, M.D.